The biotech is entering a new era.

President Stephen Hoge said the company’s recently announced positive Phase III results for its investigational personalized cancer vaccine, intismeran, in adjuvant melanoma support a broader effort ...

Moderna built an artificial intelligence that reads a patient’s tumor and decides what that patient’s medicine should be.

Moderna (MRNA) closed at $146.69 in the latest trading session, marking a +1.89% move from the prior day. The stock outperformed the S&P 500, which registered a daily loss of 0.48%. At the same time, ...

Florida pharmacies and clinics are now offering updated flu and COVID vaccines for the 2026-27 respiratory illness season, ...

Moderna and Merck's Phase 3 melanoma vaccine trial showed positive results, but full data and FDA approval are still pending ...

A cancer vaccine breakthrough sent Moderna's stock up more than 176% before a sharp pullback — a reminder of the risks ...

Doctors discovered that Johnson had stage 2B triple-negative breast cancer, a rare and aggressive form. They treated her with ...